Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

doi:10.1136/jitc-2025-013613

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Journal for immunotherapy of cancer - 3 Mar 2026

Ninmer Emily K, Petroni Gina R, Gastman Brian R, Gaughan Elizabeth M, Isaacs James M, Haden Kathleen, Kaur Varinder, Wages Nolan A, Chianese-Bullock Kimberly A, Smith Kelly T, Wright Paul, Bryant Jennifer, Dunlap-Brown Marya, Engel Jack A, Bekiranov Stefan, Mauldin Ileana S, Truong Thach-Giao, Bullock Timothy N J, Slingluff Craig L

Abstract excerpt

BACKGROUND: For patients with high-risk melanoma who are unresponsive or intolerant to immune checkpoint inhibitors, cancer vaccines may provide benefit with a favorable toxicity profile. CD4+ T cells provide essential help to dendritic cells (DCs) for optimal CD8+ T cell priming in the antitumor response, and induction of tumor-cognate CD4+ T cell responses may enhance vaccine efficacy. We report on a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, Neoplasm

Share to Cancer Vaccines

Share to CD40 Antigens

Share to Melanoma

Share to Poly I-C

Share to Proto-Oncogene Proteins B-raf

Share to Toll-Like Receptor 3

Source

Open in PubMed Open full text

Identifiers

PMID: 41775435
DOI: 10.1136/jitc-2025-013613
PMCID: PMC12959172

Genes

CD4
CD40
BRAF
TLR3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).PMID 41775435Read ↗

IMPACT - Phase Ib Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell CarcinomaSemantic proximity Read ↗

A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.Semantic proximity Read ↗

Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.Semantic proximity Read ↗

Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-VaccineSemantic proximity Read ↗

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.Semantic proximity Read ↗

Melanoma antigens recognised by CD8+ and CD4+ T cells.Semantic proximity Read ↗

Clinical efficacy and immunity of a novel immune-modulatory peptide vaccine against IDO/PD-L1 (IO102/IO103) in combination with nivolumab in patients with metastatic melanomaSemantic proximity Read ↗

Oncogene Mutations: The Shared Antigen Vaccines That Work?Semantic proximity Read ↗

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy.Semantic proximity Read ↗

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma.Semantic proximity Read ↗

Identification of highly cross-reactive mimotopes for a public T cell response in murine melanomaSemantic proximity Read ↗

Potent antitumor activity of a designed interleukin-21 mimicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.